Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bangkok Genomics Innovation PCLBKK:BKGI -2.78%45 5-Year Yield-on-Cost % is 2.38 as of Aug. 19, 2026, which is 29% below its 10-year median of 3.33. GuruFocus rates BKK:BKGI with a GF Score™ of 45/100. The stock has 12 warning signs investors should review. Among 62 Medical Diagnostics & Research companies, Bangkok Genomics Innovation PCL ranks worse than 53.23% on this metric.
The historical rank and industry rank for Bangkok Genomics Innovation PCL's 5-Year Yield-on-Cost % or its related term are showing as below:
BKK:BKGI'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.34 Med: 3.33 Max: 4.03
Current: 2.38
During the past 7 years, Bangkok Genomics Innovation PCL's highest Yield on Cost was 4.03. The lowest was 2.34. And the median was 3.33.
BKK:BKGI's 5-Year Yield-on-Cost % is ranked worse than 53.23% of 62
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.385
vs BKK:BKGI: 2.38
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Bangkok Genomics Innovation PCL 5-Year Yield-on-Cost % Related Terms
BKK:BKGI vs TMO, DHR, IDXX: 5-Year Yield-on-Cost % Comparison
For the Diagnostics & Research subindustry, Bangkok Genomics Innovation PCL's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bangkok Genomics Innovation PCL 5-Year Yield-on-Cost % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Bangkok Genomics Innovation PCL's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Bangkok Genomics Innovation PCL's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Bangkok Genomics Innovation PCL (BKK:BKGI) has a 5-Year Yield-on-Cost % of 2.38 as of Aug. 19, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Bangkok Genomics Innovation PCL and its competitors. This is 29% below median its historical median of 3.33. Over the past decade, Bangkok Genomics Innovation PCL's 5-Year Yield-on-Cost % has ranged from 2.34 to 4.03. According to the industry distribution chart, Bangkok Genomics Innovation PCL ranks #33 out of 62 companies in the Medical Diagnostics & Research industry, placing it in the top 53.2%.
Is Bangkok Genomics Innovation PCL's 5-Year Yield-on-Cost % too high?
Bangkok Genomics Innovation PCL's current 5-Year Yield-on-Cost % of 2.38 is 29% below median its 10-year median of 3.33. Over the past 10 years, this metric has ranged from a low of 2.34 to a high of 4.03. The Medical Diagnostics & Research industry median 5-Year Yield-on-Cost % is 2.39. Bangkok Genomics Innovation PCL's value of 2.38 is 0.2% below this industry median. Based on the distribution chart, Bangkok Genomics Innovation PCL ranks #33 out of 62 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Bangkok Genomics Innovation PCL has a GF Score™ of 45/100, reflecting its overall financial health beyond just this single metric.
How does Bangkok Genomics Innovation PCL's 5-Year Yield-on-Cost % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Bangkok Genomics Innovation PCL ranks #33 out of 62 companies for 5-Year Yield-on-Cost %. This places Bangkok Genomics Innovation PCL in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.39. Bangkok Genomics Innovation PCL's value of 2.38 is 0.2% below this benchmark. Historically, Bangkok Genomics Innovation PCL's own 5-Year Yield-on-Cost % has ranged from 2.34 to 4.03 over the past decade. While the company's 10-year median is 3.33 vs. the industry median of 2.39, Bangkok Genomics Innovation PCL has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Diagnostics & Research company?
The median 5-Year Yield-on-Cost % among Medical Diagnostics & Research companies is 2.39, based on 62 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bangkok Genomics Innovation PCL's current 5-Year Yield-on-Cost % of 2.38 is 0.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Bangkok Genomics Innovation PCL and its competitors. For the Medical Diagnostics & Research industry, the median 5-Year Yield-on-Cost % is 2.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bangkok Genomics Innovation PCL's current 5-Year Yield-on-Cost % is 2.38, which is 29% below median its own 10-year median of 3.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bangkok Genomics Innovation PCL stock overvalued right now?
Bangkok Genomics Innovation PCL (BKK:BKGI) has a current 5-Year Yield-on-Cost % of 2.38. The current 5-Year Yield-on-Cost % is 2.38, which is 29% below median its 10-year median of 3.33 and 0.2% below the Medical Diagnostics & Research industry median of 2.39. Bangkok Genomics Innovation PCL's overall GF Score™ is 45/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Bangkok Genomics Innovation PCL (BKK:BKGI), the current 5-Year Yield-on-Cost % is 2.38 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bangkok Genomics Innovation PCL operate a laboratory and provide medical analysis services. Its services includes Screening for genetic abnormalities in reproductive health (Reproductive Health Testing Services),Infectious Disease Analysis Product Group (Infectious - Related Testing Services), Other screening product groups (Other Testing Services), providing technology services (Tech Solution Services), and Sales of other medical products Related (Medical - Related Products). Its segments include Sale of laboratory reagents and related products; Testing and analysis services, which derives maximum revenue; and Sale and advanced therapy medicinal product.
45GF Score
Get the complete analysis for BKK:BKGI
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:BKGI has been successfully added to your 
